Actively Recruiting
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
Led by Samsung Medical Center · Updated on 2024-06-20
88
Participants Needed
1
Research Sites
356 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.
CONDITIONS
Official Title
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with metastatic renal cell carcinoma having 5 or fewer metastases and 3 or fewer metastatic organs, including new, recurrent, or induced metastases
- Aged between 20 and 80 years
- Individual metastases measuring 5 cm or less in longest diameter
- Primary tumor surgically removed or scheduled for surgery
- Histologically confirmed clear cell carcinoma
- ECOG performance status of 0 or 1
- Normal major organ and bone marrow function with WBC ≥ 2,000/µL, neutrophils ≥ 1,000/µL, and platelets ≥ 50,000/µL
- Able to understand and voluntarily sign informed consent
- Agree to use contraception from consent signing until 1 year after last systemic therapy
- Breastfeeding women agree to stop breastfeeding for at least 5 months after last systemic therapy
- Presence of visible tumors outside the surgical removal area for metastatic lesions
You will not qualify if you...
- Total bilirubin level above 3.6 mg/dL
- AST levels above 160 U/L or ALT levels above 165 U/L
- Unable to maintain position for partial nephrectomy radiotherapy
- Previous radiotherapy to metastatic renal cell carcinoma or surrounding areas
- Presence of brain, peritoneal, or pleural metastases
- Diagnosed with another solid tumor treated within 2 years or with residual lesions
- Refusal to consent to participate in the study
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
W
Won Park, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here